Professor Chris Van Tulleken to Headline Smart Ageing Summit in May

Feb 23, 2026 | News

Image Source: The Oxford Longevity Project
Written by: Contributor
On behalf of: Life Science Daily News

After the success of previous summits, the revolutionary Smart Ageing Summit has announced a return to Oxford this May to host its fourth annual event. Rhodes House, University of Oxford is the perfect setting for non-profit organisation Oxford Health Project to host this year’s summit which is dedicated to the theme of diet and longevity.

Taking place on Saturday 9th May, the Smart Ageing Summit is set to be a fascinating day for all attendees who want powerful insights and practical tools to aid them in a diet for not just lifespan but healthspan.  Leading longevity scientists, doctors, and thinkers hailing from around the world will head to the magnificent Rhodes House for the annual summit. 

A familiar face on our TV screens, Professor Chris van Tulleken will deliver the keynote address, best known for being the author of the hit New York Times bestseller Ultraprocessed people. He will be joined by an outstanding line-up of speakers, including YouTube sensation and ketone and fasting expert, Dr Nick Norwitz, Lifestyle Medicine Doctor & Obesity Expert Dr Ellen Fallows, Prof John Todd, diabetes expert, and Prof Mark Kendall, Rolex Scientist of the Year and hydration expert, with topics that will be discussed including food systems, GLPS1s, hydration, cooking for health and longevity and keto diets.

With the focus of this year being the link between diet and longevity, guests will enjoy generous gourmet catering, with thoughtfully prepared options to accommodate all food sensitivities and dietary preferences. Previous attendees will also know to expect energising movement breaks and a joyful, engaging atmosphere throughout the day, in line with The Oxford Longevity Project’s Live Longer Better Plan.

Early Bird tickets are on sale now (until the end of February) with a variety of ticket choices from accessible options without lunch to premium VIP experiences. 

“We all know that connecting with our tribe and living in vibrant communities is one of the keys to longer, healthier lives, so we are excited to again be bringing together this group of leading researchers and practitioners to discuss the science of ageing, while also offering attendees a unique opportunity to experience the collegial magic of an Oxford college. After the success of last year, Oxford Healthspan is also proud to sponsor this important event with the topic of diet and longevity being so crucial to healthspan,” says Co-Founder of the Oxford Longevity Project and CEO of Oxford Healthspan Leslie Kenny.

About the Oxford Longevity Project and Oxford Healthspan

The Oxford Longevity Project is a not-for-profit project that produces public service webinars around the latest scientific breakthroughs on ageing, with a particular focus on autophagy and cellular renewal. The project was founded by Oxford Professors Denis Noble and Sir Christopher Ball, Oxford College doctor Dr. Paul Ch’en, and Harvard MBA and Oxford-based patient advocate Leslie Kenny, with Sir Muir Gray joining the board in 2024.

The Smart Ageing Summit is sponsored by Oxford Healthspan.

For more information on the Smart Ageing Summit, visit: https://oxfordlongevityproject.org/smart-ageing-summit 

    References: None.

    Articles that may be of interest

    Weekly News Roundup | 13 April 2026

    Weekly News Roundup | 13 April 2026

    Life science news 13 April 2026: A record-breaking wave of M&A, an escalating GLP-1 pricing war and major FDA approvals define a landmark week for the global life science industry. Gilead Sciences announced on 7 April its acquisition of Munich-based antibody-drug...

    read more
    Weekly News Roundup | 6 April 2026

    Weekly News Roundup | 6 April 2026

    Life science news 6 April 2026: A landmark obesity pill approval, 100% pharma tariffs and a record $6.3 billion life sciences fund headline a transformative week for the global pharmaceutical industry. The FDA approved Eli Lilly's once-daily obesity pill Foundayo...

    read more
    Python Blood Molecule Opens Door to New Obesity Treatments

    Python Blood Molecule Opens Door to New Obesity Treatments

    Scientists studying the extraordinary metabolism of Burmese pythons have identified a python blood molecule that dramatically suppresses appetite in obese mice, raising the prospect of a new class of weight loss therapies that could avoid some of the side effects...

    read more
    Weekly News Roundup | 30 March 2026

    Weekly News Roundup | 30 March 2026

    Life science news 30 March 2026: Three blockbuster deals, two FDA accelerated approvals and intensifying GLP-1 competition headline a busy week for pharma and biotech. Merck agreed on 25 March to acquire Terns Pharmaceuticals for $6.7 billion, gaining access to...

    read more

    Articles that may be of interest

    Weekly News Roundup | 13 April 2026

    Weekly News Roundup | 13 April 2026

    Life science news 13 April 2026: A record-breaking wave of M&A, an escalating GLP-1 pricing war and major FDA approvals define a landmark week for the global life science industry. Gilead Sciences announced on 7 April its acquisition of Munich-based antibody-drug...

    read more
    Weekly News Roundup | 6 April 2026

    Weekly News Roundup | 6 April 2026

    Life science news 6 April 2026: A landmark obesity pill approval, 100% pharma tariffs and a record $6.3 billion life sciences fund headline a transformative week for the global pharmaceutical industry. The FDA approved Eli Lilly's once-daily obesity pill Foundayo...

    read more
    Python Blood Molecule Opens Door to New Obesity Treatments

    Python Blood Molecule Opens Door to New Obesity Treatments

    Scientists studying the extraordinary metabolism of Burmese pythons have identified a python blood molecule that dramatically suppresses appetite in obese mice, raising the prospect of a new class of weight loss therapies that could avoid some of the side effects...

    read more
    Weekly News Roundup | 30 March 2026

    Weekly News Roundup | 30 March 2026

    Life science news 30 March 2026: Three blockbuster deals, two FDA accelerated approvals and intensifying GLP-1 competition headline a busy week for pharma and biotech. Merck agreed on 25 March to acquire Terns Pharmaceuticals for $6.7 billion, gaining access to...

    read more